CCME Global Ltd
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
- Market Cap ₹ 124 Cr.
- Current Price ₹ 27.5
- High / Low ₹ 185 / 26.4
- Stock P/E
- Book Value ₹ 8.86
- Dividend Yield 0.00 %
- ROCE -2.92 %
- ROE -2.92 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.10 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.66% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | |
| 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.75 | 0.87 | |
| Operating Profit | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.71 | -0.83 |
| OPM % | -19.23% | -68.97% | -100.00% | 95.37% | -1,775.00% | -2,075.00% | |||||||
| -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Profit before tax | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.71 | -0.85 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.71 | -0.85 | |
| EPS in Rs | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.16 | -0.24 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -99% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 27% |
| 3 Years: | 35% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| Last Year: | -3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 45.25 |
| Reserves | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -5.18 |
| 0.17 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 5.24 | |
| Total Liabilities | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 | |
| Total Assets | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 | 5.10 | |
| 0.77 | 0.00 | 0.00 | -4.66 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 4.10 | 2.62 | 0.26 | 3.00 | 0.00 | 0.00 | 0.12 | 0.12 | 0.09 | 0.00 | 0.00 | 32.25 | |
| Net Cash Flow | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 37.35 |
| Free Cash Flow | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 | 5.10 |
| CFO/OP | 3,240% | 3,771% | 357% | -840% | 9,380% | -10% | 100% | 100% | 64% | 0% | 0% | -718% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229.29 | 62.93 | 292.00 | 0.00 | ||||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 229.29 | 62.93 | 292.00 | 0.00 | ||||||||
| Working Capital Days | 1,586.35 | 5,991.03 | 67,890.00 | 24,728.75 | ||||||||
| ROCE % | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% | -2.92% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Equity Shares Outstanding shares |
|
||||||||||
| Promoter Shareholding % |
|||||||||||
| Number of Shareholders count |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Post dispatch newspaper publication for AGM Notice.
- Closure Of Register Of Members For The Purpose Of AGM.
- Notice Of The 34Th Annual General Meeting Of CCME Global Limited
- Reg. 34 (1) Annual Report.
-
Clarification On Minor Typo Errors In Outcome And Intimations Filed After Board Meeting Held On 29Th August, 2026.
- Clarifies typos in 29 Aug 2026 board meeting and preferential issue disclosure; details unchanged.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Transition
The company historically described itself as a biotechnology and probiotic products business. However, it reported no operating income during FY23–FY25 and stated that it did not have an operating business. [1][2][3]
In April 2024, shareholders replaced the biotechnology objects with gold, jewellery and precious-metals activities, but no revenue was subsequently generated from this business. In FY26, these objects were again replaced with manufacturing, processing, trading, import and export of FMCG products, commodities and minerals. Management intends to export Indian FMCG products, particularly to Middle Eastern markets, but this remains a proposed activity.[4][5][6][7]